Age

19–any

Sex

ALL

Healthy volunteers

Not accepted

Triple negative breast cancer
Subjects administered neoadjuvant Weekly paclitaxel, Carboplatin followed by Doxorubicin, Cyclophosphamide add Pembrolizumab or not
Non pCR patients who are undergoing surgery after neoadjuvant chemotherapy
Sign to informed consent

Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer